The effect of Fluoxetine on lipid profiles in overweight or obese Individuals: A systematic review and meta-analysis of randomized controlled trials
Authors' conclusion
Fluoxetine significantly lowers TG and raises HDL-C in overweight or obese individuals. The effect on TG is more pronounced at 60 mg/day and in shorter interventions. Further research is needed to evaluate long-term impacts.
Study context
- Population
- Overweight or obese individuals; RCTs in Scopus, PubMed/Medline, Web of Science and Embase up to December 20249 studies
- Comparison
- Fluoxetine vs control
- Outcome
- Lipid profiles (TG, HDL-C, total cholesterol, LDL-C)
Methodological detailsrandom-effects model (DerSimonian and Laird)
- Random-effects model (DerSimonian and Laird)
Pooled result
As reported in the abstract
Lipid profile (pooled WMD)
FluoxetineEstimate (95% CI)P value
TG significantly reduced
WMD (TG) −22.04 mg/dL(−42.61 to −1.46)
P = 0.036HDL-C increased
WMD (HDL-C) 2.25 mg/dL(0.21–4.28)
P = 0.030Further pooled results
Triglycerides (TG), subgroups
mg/dL
- TG weighted mean differences (WMD) with 60 mg/day fluoxetine
- −43.86
- TG WMD with baseline TG ≥ 150 mg/dL
- −26.62
- TG WMD with interventions ≤ 12 weeks
- −26.88
Original publication
The effect of Fluoxetine on lipid profiles in overweight or obese Individuals: A systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. Published 18 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →